The Biolocity Team is excited to partner with Additional Ventures to assist in identifying promising research at both Georgia Tech and Emory University that provides solutions for single ventricle heart defects. To learn about this partnership, read more here.
Biolocity’s annual funding cycle is now open for the acceleration of university innovations! Faculty in search of funding and commercialization guidance to meet strategic development milestones for commercial success are encouraged to apply.
Faculty at Georgia Tech, Emory University, and Georgia State University have been selected to receive a broad range of support from Biolocity to accelerate the commercialization of their patient impacting technologies. During their funding period, each team will receive project management and work directly with business experts and consultants to de-risk their technology and advance its development. [Read more…] about Technologies Selected for Biolocity Commercialization Funding
Biolocity stems from the expansion of a successful five year pilot in which the program awarded over $6.2 million to 40 innovative projects leading to 20 start-ups, and three products on the market. As a result of the Coulter Fund’s successful pilot and the increasing demands for translational funding and mentorship, Biolocity was created to address the need for a broader network of support for university innovators.
“Biolocity extends our successful Coulter Translational Program model to reach a larger, more diverse cohort of innovators at earlier stages of their discovery, guides them using our successful experts-in-residence process, and cultivates individualized links with the commercialization ecosystem,” said Susan Margulies, Chair of the Wallace H. Coulter Department of Biomedical Engineering.
Similar to the Coulter program, Biolocity provides university innovators with a combination of investment, resources, and guidance that early-stage medical technologies need to reach critical commercialization milestones. We utilize three collaborative methods to advance translational science to the marketplace:
Bringing both the experience and success of the Coulter process, Biolocity creates a multi-institutional network to support the commercialization of medical technology in the southeast. The program adds new connectivity across Atlanta, while deepening its commitment to Emory University and the Georgia Institute of Technology.
“We are grateful to the Coulter Foundation’s support our pilot and proud of our teams’ successes”, said Shawna Khouri, managing director of Biolocity. “As our program evolves and continues to grow as Biolocity, we look forward to expanding our network with new partners and adding connections within the Atlanta biotech ecosystem.”
To learn more about Biolocity’s upcoming funding cycle and educational opportunities, visit www.biolocity.org.
The Coulter Translational Program, in partnership with the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, awarded $765,000 to six biomedical research projects. These awards help bring innovations in patient care into the marketplace.
The Coulter program fund provides annual awards to Emory University and Georgia Institute of Technology research teams who create products with commercial potential that address an unmet clinical need. Funding and project management provided by the Coulter program team is used to bridge the gap in development between early stage university research and its commercialization.
Out of 54 applications in this year’s funding cycle, the below innovative projects were selected by a committee comprised of venture capitalists, industry, entrepreneurs, doctors, biomedical engineers and technology transfer experts from both universities.
“There is a rich pipeline of commercializable patient-impacting technologies at Georgia Tech and Emory University. This year’s applicant pool was exceedingly competitive” says Shawna Khouri, managing director of the Coulter Translational Program. “The projects selected to be a part of this cohort have a strong potential for commercialization and we’re eager to work with our PIs to grow these opportunities and advance them aggressively toward the market.”
